Consolidated Statements of Cash Flows Statement (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Cash flows from operating activities:
Net income (loss) including noncontrolling interests in operating subsidiaries	$ 5,113,000	$ 49,653,000
Adjustments to reconcile net income including noncontrolling interests in operating subsidiaries to net cash provided by operating activities:
Depreciation and amortization	11,774,000	5,158,000
Non-cash stock compensation	5,158,000	5,090,000
Excess tax benefits from stock-based compensation	709,000	7,611,000
Change in valuation allowance	0	(10,237,000)
Changes in assets and liabilities:
Accounts receivable	(35,508,000)	1,635,000
Prepaid expenses and other assets	(1,661,000)	(919,000)
Accounts payable and accrued expenses / costs	8,430,000	10,303,000
Royalties and contingent legal fees payable	24,228,000	(9,413,000)
Deferred income tax	0	5,293,000
Net cash provided by operating activities	16,825,000	48,952,000
Cash flows from investing activities:
Purchases of property and equipment	(241,000)	(24,000)
Purchase of available-for-sale investments	(97,225,000)	(144,762,000)
Maturities and sale of available-for-sale investments	53,262,000	20,000,000
Purchase of ADAPTIX, Inc., net of cash acquired	0	(150,000,000)
Patent acquisition costs	(4,010,000)	(2,100,000)
Net cash used in investing activities	(48,214,000)	(276,886,000)
Cash flows from financing activities:
Proceeds from sale of common stock, net of issuance costs	0	219,084,000
Contributions from noncontrolling interests in operating subsidiary	1,920,000	1,920,000
Excess tax benefits from stock-based compensation	709,000	7,611,000
Proceeds from exercises of stock options	117,000	84,000
Net cash provided by financing activities	2,746,000	228,699,000
(Decrease) increase in cash and cash equivalents	(28,643,000)	765,000
Cash and cash equivalents, beginning	221,804,000	314,733,000
Cash and cash equivalents, ending	$ 193,161,000	$ 315,498,000